Evidence map›Paper›PMID 41049505›Full record

ArticleAmerican journal of ophthalmology case reports2025

High-dose topotecan (90 and 180 μG) for recurrent subretinal and vitreous seeding in retinoblastoma.

David H Abramson, Jasmine H Francis

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of ophthalmology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

David H AbramsonDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, N.Y, USA.
Jasmine H FrancisDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, N.Y, USA.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Purpose: To report on the use of intravitreal high-dose topotecan (90 and 180 μG) for recurrent subretinal and vitreous retinoblastoma, the toxicity of these injections, and the use of a 180-μG injection of intravitreal topotecan in humans. Observations: High-dose (90 and 180 μG) intravitreal topotecan was effective in treating recurrent subretinal and vitreous retinoblastoma without anterior segment or retinal toxicity or altered electroretinogram function in two cases. Conclusion and importance: Recurrent subretinal and vitreous retinoblastoma after intraarterial chemotherapy are difficult to treat. High-dose intravitreal topotecan (90 and 180 μG) was used to salvage two such eyes without measurable toxicity.

Indexed as

Diode laserIntravitreal injectionOphthalmic artery chemosurgeryRecurrent retinoblastomaRetinoblastomaSubretinal retinoblastomaTopotecanVitreous retinoblastoma

Identifiers

PMID41049505
PMCPMC12489761

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.